Trevi Therapeutics (TRVI) Other Non-Current Assets (2018 - 2026)
Trevi Therapeutics' quarterly Other Non-Current Assets came in at $2.6 million in Q1 2026, up 982.99% year-on-year from $241000.0 in Q1 2025, and up 181.25% quarter-over-quarter from $928000.0 in Q4 2025.
Trevi Therapeutics has reported Other Non-Current Assets for 9 years, with the latest figure at $2.6 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets rose 982.99% year-over-year to $2.6 million; the trailing twelve-month figure through Mar 2026 stood at $2.6 million (up 982.99% YoY), and the FY2025 full-year result was $928000.0, up 281.89% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $2.6 million, up from $928000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $2.6 million in Q1 2026, with the low at $68000.0 in Q2 2023.
- Average Other Non-Current Assets over 5 years is $462235.3, with a median of $273000.0 recorded in 2024.
- Year-over-year, Other Non-Current Assets slumped 83.54% in 2023 and surged 982.99% in 2026.
- Tracing TRVI's Other Non-Current Assets over 5 years: stood at $205000.0 in 2022, then soared by 44.88% to $297000.0 in 2023, then fell by 18.18% to $243000.0 in 2024, then jumped by 281.89% to $928000.0 in 2025, then jumped by 181.25% to $2.6 million in 2026.
- The last three Other Non-Current Assets figures came in at $2.6 million (Q1 2026), $928000.0 (Q4 2025), and $103000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - | 2.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.61 Mn |
| Dec 31, 2025 | 928,000.00 |
| Sep 30, 2025 | 103,000.00 |
| Jun 30, 2025 | 68,000.00 |
| Mar 31, 2025 | 241,000.00 |
| Dec 31, 2024 | 243,000.00 |
| Sep 30, 2024 | 256,000.00 |
| Jun 30, 2024 | 273,000.00 |
| Mar 31, 2024 | 311,000.00 |
| Dec 31, 2023 | 297,000.00 |
| Sep 30, 2023 | 297,000.00 |
| Jun 30, 2023 | 68,000.00 |
| Mar 31, 2023 | 225,000.00 |
| Dec 31, 2022 | 205,000.00 |
| Sep 30, 2022 | 922,000.00 |
| Jun 30, 2022 | 413,000.00 |
| Mar 31, 2022 | 398,000.00 |
| Dec 31, 2021 | 334,000.00 |
| Dec 31, 2020 | 532,000.00 |
| Sep 30, 2020 | 19,000.00 |
| Jun 30, 2020 | 19,000.00 |
| Mar 31, 2020 | 19,000.00 |
| Dec 31, 2019 | 19,000.00 |
| Sep 30, 2019 | 19,000.00 |
| Jun 30, 2019 | 19,000.00 |
| Mar 31, 2019 | 19,000.00 |
| Dec 31, 2018 | 19,000.00 |